JP2012518029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518029A5 JP2012518029A5 JP2011550560A JP2011550560A JP2012518029A5 JP 2012518029 A5 JP2012518029 A5 JP 2012518029A5 JP 2011550560 A JP2011550560 A JP 2011550560A JP 2011550560 A JP2011550560 A JP 2011550560A JP 2012518029 A5 JP2012518029 A5 JP 2012518029A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- integer
- derivative
- moiety
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010054218 Factor VIII Proteins 0.000 claims 24
- 102000001690 Factor VIII Human genes 0.000 claims 24
- 229960000301 factor viii Drugs 0.000 claims 24
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004506 Blood Proteins Human genes 0.000 claims 2
- 108010017384 Blood Proteins Proteins 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 2
- 108060008539 Transglutaminase Proteins 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000003601 transglutaminase Human genes 0.000 claims 2
- 101000666171 Homo sapiens Protein-glutamine gamma-glutamyltransferase 2 Proteins 0.000 claims 1
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 claims 1
- 241001495137 Streptomyces mobaraensis Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- ARMXDLIWGUZMEW-UHFFFAOYSA-N CC(NOBON)=O Chemical compound CC(NOBON)=O ARMXDLIWGUZMEW-UHFFFAOYSA-N 0.000 description 2
- VBCQTQTWKCGJMT-UHFFFAOYSA-N CC(NOBO/N=C/N)=O Chemical compound CC(NOBO/N=C/N)=O VBCQTQTWKCGJMT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153257 | 2009-02-19 | ||
| EP09153257.2 | 2009-02-19 | ||
| US16151009P | 2009-03-19 | 2009-03-19 | |
| US61/161,510 | 2009-03-19 | ||
| PCT/EP2010/052022 WO2010102886A1 (en) | 2009-02-19 | 2010-02-18 | Modification of factor viii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012518029A JP2012518029A (ja) | 2012-08-09 |
| JP2012518029A5 true JP2012518029A5 (enExample) | 2013-04-04 |
Family
ID=40935766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011550560A Withdrawn JP2012518029A (ja) | 2009-02-19 | 2010-02-18 | 第ｖｉｉｉ因子の修飾 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110306551A1 (enExample) |
| EP (1) | EP2398822B1 (enExample) |
| JP (1) | JP2012518029A (enExample) |
| CN (1) | CN102333788A (enExample) |
| ES (1) | ES2401965T3 (enExample) |
| WO (1) | WO2010102886A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| CN102112157B (zh) | 2008-08-06 | 2013-05-29 | 诺沃-诺迪斯克保健股份有限公司 | 具有延长的体内效能的缀合蛋白 |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| MX2012001207A (es) * | 2009-07-27 | 2012-05-08 | Baxter Int | Conjugados proteicos de coagulacion sanguínea. |
| PL2459224T3 (pl) | 2009-07-27 | 2017-08-31 | Baxalta GmbH | Koniugaty białka związanego z krzepnięciem krwi |
| EP2461831B1 (en) | 2009-08-06 | 2018-11-21 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
| CN103002918B (zh) | 2010-01-22 | 2016-05-04 | 诺沃—诺迪斯克保健股份有限公司 | 体内功效延长的生长激素 |
| RU2012134974A (ru) | 2010-01-22 | 2014-02-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированное соединение гормона роста |
| JP5914363B2 (ja) | 2010-02-16 | 2016-05-11 | ノヴォ ノルディスク アー／エス | 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子 |
| RU2013131911A (ru) * | 2010-12-16 | 2015-01-27 | Ново Нордиск А/С | Водный раствор фактора viii |
| PL2654794T3 (pl) | 2010-12-22 | 2020-07-27 | Baxalta GmbH | Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem |
| BR112014006684A2 (pt) | 2011-09-23 | 2017-03-28 | Novo Nordisk As | análogos de glucagon |
| JP2015513666A (ja) * | 2012-02-17 | 2015-05-14 | エヌブイエス テクノロジーズ，インコーポレイティド | アッセイへの適用のためのポリマー骨格 |
| WO2014026954A1 (en) * | 2012-08-13 | 2014-02-20 | Novo Nordisk A/S | Liquid factor viii formulations |
| EP2941423B1 (en) | 2013-01-07 | 2021-06-09 | University of Southern California | Deoxyuridine triphosphatase inhibitors |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| EP3016975B1 (en) | 2013-07-04 | 2019-01-16 | Novo Nordisk A/S | Derivatives of glp-1 like peptides, and uses thereof |
| EP3613755A1 (en) | 2013-07-11 | 2020-02-26 | Novartis AG | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| EP3089964B1 (en) | 2014-01-03 | 2021-02-24 | University Of Southern California | Heteroatom-containing deoxyuridine triphosphatase inhibitors |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| PL3177317T3 (pl) | 2014-08-04 | 2020-07-27 | Csl Limited | Formulacja czynnika viii |
| EP3252040B1 (en) | 2015-01-27 | 2023-04-19 | BGI Shenzhen | Stabilizer for preserving biological samples |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| US10570100B2 (en) | 2015-07-08 | 2020-02-25 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| ES3016670T3 (en) | 2015-07-08 | 2025-05-09 | Cv6 Therapeutics Ni Ltd | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| CN108699126B (zh) | 2016-03-03 | 2022-12-06 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| WO2018098206A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10829457B2 (en) | 2016-11-23 | 2020-11-10 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| WO2018098207A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| WO2018128720A1 (en) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
| WO2019016300A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | EGF ANALOGUES (A), PREPARATION, FORMULATIONS AND USES THEREOF |
| CN110945017B (zh) | 2017-07-19 | 2024-07-16 | 诺和诺德股份有限公司 | 双功能化合物 |
| WO2019229242A1 (en) | 2018-05-31 | 2019-12-05 | Novo Nordisk A/S | Derivatives comprising an apelin analogue and uses thereof |
| JP7780341B2 (ja) | 2019-07-04 | 2025-12-04 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 第ＶＩＩＩ凝固因子のｉｎ ｖｉｔｒｏでの安定性を向上させるための切断型フォン・ヴィレブランド因子（ＶＷＦ） |
| WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| US20250268986A1 (en) | 2020-11-06 | 2025-08-28 | Novo Nordisk A/S | Glp-1 prodrugs and uses thereof |
| WO2023285334A1 (en) | 2021-07-12 | 2023-01-19 | Novo Nordisk A/S | Novel fatty acid modified urocortin 2 derivatives and the uses thereof |
| WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
| KR20250150662A (ko) | 2022-11-02 | 2025-10-20 | 노보 노르디스크 에이/에스 | Cnp 화합물 |
| CN120435491A (zh) | 2022-12-22 | 2025-08-05 | 诺和诺德股份有限公司 | 胰淀素受体激动剂 |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| KR20240163292A (ko) * | 2023-05-10 | 2024-11-19 | 주식회사 아미노로직스 | 모노-터트-부틸 에스터화된 포화 탄화수소의 제조방법 및 이의 순환적 제조방법 |
| KR20250083391A (ko) | 2023-11-30 | 2025-06-10 | 노보 노르디스크 에이/에스 | Glp-1, gip, 및 아밀린 수용체의 삼중작용제 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0665280B2 (ja) | 1987-03-04 | 1994-08-24 | 味の素株式会社 | タンパクゲル化剤及びそれを用いるタンパクのゲル化方法 |
| JP2849773B2 (ja) | 1990-08-27 | 1999-01-27 | 天野製薬株式会社 | ストレプトミセス属由来のトランスグルタミナーゼの製造法 |
| EP0555649B1 (en) | 1992-01-14 | 2004-12-08 | Ajinomoto Co., Inc. | Gene encoding transglutaminase derived from fish |
| DK128193D0 (da) | 1993-11-12 | 1993-11-12 | Novo Nordisk As | Hidtil ukendte forbindelser |
| WO1995020662A1 (en) | 1994-01-28 | 1995-08-03 | Ajinomoto Co., Inc. | Transglutaminase originating in japanese oyster |
| US6100053A (en) | 1994-08-26 | 2000-08-08 | Novo Nordisk A/S | Microbial transglutaminases, their production and use |
| BR9606772A (pt) | 1995-01-19 | 1998-01-06 | Novo Nordisk As | Preparação de transglutaminase processos para produção da mesma e de uma enzima que exibe atividade transglutaminase e para reticulação de proteínas transglutaminase originária construção de dna vetor de expressão recombinante célula enzima composição de transglutaminase e uso da preparação de transglutaminase |
| JP3669390B2 (ja) | 1995-02-09 | 2005-07-06 | 味の素株式会社 | バチルス属細菌由来のトランスグルタミナーゼ |
| AU7381098A (en) * | 1997-05-16 | 1998-12-08 | Novo Nordisk Biotech, Inc. | Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP2003199569A (ja) | 2001-12-17 | 2003-07-15 | Food Industry Research & Development Inst | ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ |
| KR101085375B1 (ko) * | 2003-02-26 | 2011-11-21 | 넥타르 테라퓨틱스 | 중합체-인자 ⅷ 부분 콘쥬게이트 |
| MXPA06008209A (es) * | 2004-01-21 | 2006-08-31 | Novo Nordisk As | Conjugacion de peptidos mediada por transglutaminasa. |
| US20070105770A1 (en) * | 2004-01-21 | 2007-05-10 | Novo Nordisk A/S | Transglutaminase mediated conjugation of peptides |
| ES2821832T3 (es) * | 2004-11-12 | 2021-04-27 | Bayer Healthcare Llc | Modificación de FVIII dirigida al sitio |
| KR20080108147A (ko) * | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| EP2101821B1 (en) | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
-
2010
- 2010-02-18 JP JP2011550560A patent/JP2012518029A/ja not_active Withdrawn
- 2010-02-18 WO PCT/EP2010/052022 patent/WO2010102886A1/en not_active Ceased
- 2010-02-18 US US13/146,760 patent/US20110306551A1/en not_active Abandoned
- 2010-02-18 CN CN2010800074950A patent/CN102333788A/zh active Pending
- 2010-02-18 EP EP10704152A patent/EP2398822B1/en not_active Not-in-force
- 2010-02-18 ES ES10704152T patent/ES2401965T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518029A5 (enExample) | ||
| US10604526B2 (en) | Chemokine receptor modulators and uses thereof | |
| RU2016130933A (ru) | Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов | |
| ES2577514T3 (es) | Antagonistas de TLR | |
| JP2016153410A5 (enExample) | ||
| JP2017536344A5 (enExample) | ||
| JP2019512478A5 (enExample) | ||
| JP2018504378A5 (enExample) | ||
| JP2014516991A5 (enExample) | ||
| JP2010521485A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2016534059A5 (enExample) | ||
| JP2018521135A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2017515901A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| JP2018507197A5 (enExample) | ||
| JP2018504379A5 (enExample) | ||
| RU2015119561A (ru) | Новые конъюгаты лекарственное вещество-белок | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| JP2017511321A5 (enExample) | ||
| JP2025081512A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| JP2014515406A5 (enExample) | ||
| RU2016144055A (ru) | Конъюгаты лекарственного средства с наночастицами |